Shaji Kumar, MD
Hematology · Rochester, MNNPI 1568434090
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $368,738 of the $451,977 with a category attached, or 81.6%. 30 manufacturers reported payments, led by Janssen Research & Development, LLC at 30.8% of the total. Reporting peaked in 2021 at $124,296 and has fallen 74.5% since, to $31,645 in 2025. Among hematology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $1875.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$139K
- Takeda Pharmaceuticals U.S.A., Inc.$55K
- AbbVie$47K
- Regeneron$25K
- Takeda$25K
- E.r. Squibb & Sons, L.L.C.$23K
- plus $138K from 24 others
Across 725 payments — averaging $40,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$9M
- AbbVie$6M
- GSK$3.7M
- Amgen$2.6M
- Bristol Myers Squibb$2.5M
- Janssen Research & Development, LLC$2.1M
- plus $3.3M from 12 others
What the payments were for
- Consulting fees$368,73882%
- Speaking & faculty fees$53,99912%
- Grants$1870%
- Travel & lodging$25,1976%
- Food & beverage$2,7261%
- Education$1,1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 16 | $139,144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $55,455 |
| AbbVie | 45 | $46,832 |
| Regeneron | 21 | $25,406 |
| Takeda | 3 | $24,883 |
| E.r. Squibb & Sons, L.L.C. | 9 | $22,577 |
| Janssen Global Services, LLC | 20 | $20,911 |
| Bristol Myers Squibb | 11 | $15,051 |
| GSK | 11 | $13,317 |
| Genentech, Inc. | 10 | $12,810 |
| Sanofi | 5 | $9,326 |
| Amgen | 5 | $8,466 |
| Janssen Scientific Affairs, LLC | 1 | $8,400 |
| Pfizer | 3 | $8,253 |
| Gilead(2 entities) | 4 | $6,640 |
| Takeda Pharmaceutical Company, Limited | 1 | $6,400 |
| Celltrion, Inc. | 1 | $5,445 |
| F. Hoffmann-la Roche AG | 4 | $4,180 |
| Legend Biotech USA Inc. | 5 | $3,181 |
| Epizyme, Inc. | 1 | $2,700 |
| Beigene, Ltd. | 1 | $2,275 |
| Johnson & Johnson | 4 | $2,066 |
| BD | 1 | $2,000 |
| AstraZeneca | 19 | $1,910 |
| Biolinerx USA, Inc. | 1 | $1,563 |
| Dr.reddy's Laboratories,inc. | 1 | $1,500 |
| Taiho Oncology, Inc. | 10 | $762 |
| The Binding Site Inc. | 1 | $300 |
| Secura Bio, Inc. | 1 | $200 |
| Beigene USA, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$451,977 in reported general payments places this provider in the 95th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 17 | $291,912 |
| Lenalidomide | 13 | $175,311 |
| Acyclovir | 27 | $342 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $15,051 | $291,91217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 hematology providers in Minnesota.
Other hematology in Rochester
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
- Thomas WitzigRochester$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.